ELAN REPORTS 47% REDUCTION IN GASTROINTESTINAL SIDE EFFECTS WITH NAPRELAN NAPROXEN V. SYNTEX' NAPROSYN IN COMPARISON TRIALS; VERELAN SALES ARE $100 MIL.